Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial

References

• Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274–82.
   PubMed Web of Science ®Google Scholar
• Jia D, O’Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592–9.
   PubMed Web of Science ®Google Scholar
• Canalis E. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae. Endocrinology 1983;112:931–9.
   PubMed Web of Science ®Google Scholar
• Advani S, Lafrancis D, Bogdanovic E, Taxel P, Raisz LG, Kream BE. Dexamethasone suppresses in vivo levels of bone collagen synthesis in neonatal mice. Bone 1997;20:41–6.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3104–12.
   PubMed Web of Science ®Google Scholar
• Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R. Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 2001;60:521–2.
   PubMed Web of Science ®Google Scholar
• Dolan AL, Moniz C, Dasgupta B, Li F, Mackintosh C, Todd P, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997; 40:2022–9.
   PubMedGoogle Scholar
• Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister RF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115–23.
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515–26.
   PubMed Web of Science ®Google Scholar
• Emkey RD, Ettinger R. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119:S18–24.
   PubMed Web of Science ®Google Scholar
• Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, et al. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt) 2009;18:935–43.
   PubMed Web of Science ®Google Scholar
• Osteoporosis (online). Current Care guideline. Working group set up by the Finnish Medical Society Duodecim, Finnish Endocrine Society and Finnish Gynaecological Association. Helsinki: Finnish Medical Society Duodecim, 2006. Available from: www.kaypahoito.fi/web/english/home.
   Google Scholar
• Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006;17:716–23.
   PubMed Web of Science ®Google Scholar
• Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277–85.
   PubMed Web of Science ®Google Scholar
• Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009;36:1705–14.
   PubMed Web of Science ®Google Scholar
• Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23.
   PubMed Web of Science ®Google Scholar
• Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 2007;56:3518–22.
   PubMed Web of Science ®Google Scholar
• Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14:801–7.
   PubMed Web of Science ®Google Scholar
• Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011;71:65–78.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560–7.
   PubMed Web of Science ®Google Scholar